Feb | 1 | 2024
Remix Therapeutics™ Appoints Dominic Reynolds, Ph.D., as Chief Scientific Officer
Dr. Reynolds brings over two decades of leadership experience building biotech companies transformative platforms and drug discovery and development Watertown, Mass. (February 1, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced the appointment of Dominic Reynolds, Ph.D., […]
Our proprietary platform designs small molecules that harness cellular machineries to control RNA processing and modulate expression of disease drivers.
Identifying druggable high value targets
Functional target validation and multiplexed HTS assays
Compound identification and optimization from proprietary library
It's Sound Science
Remix™ launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.
Become a Remixer
Remix™ welcomes new people and perspectives to join us in pushing scientific boundaries to offer new hope to patients.